Sucralfate: nonulcer uses. American College of Gastroenterology Committee on FDA-Related Matters.
Recent studies have shown sucralfate to have cytoprotective features in addition to its known antipepsin and antacid effects. This drug has been shown in limited studies to prevent gastric salicylate injury with pretreatment. A role for sucralfate in the nonulcer population, patients with gastritis, esophagitis, stomatitis, while promising, has not been clearly established and needs to be defined with further studies.
D000327:Adsorption; D000535:Aluminum / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001647:Bile Acids and Salts; D001655:Bile Reflux / Q000188:drug therapy; D003451:Cryoprotective Agents; D004066:Digestive System Diseases / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000188:drug therapy; D005756:Gastritis / Q000188:drug therapy; D006801:Humans; D013280:Stomatitis / Q000188:drug therapy; D013392:Sucralfate
D000893:Anti-Inflammatory Agents; D001647:Bile Acids and Salts; D003451:Cryoprotective Agents; D013392:Sucralfate; D000535:Aluminum